Article
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Thoracic cancer - 1 Mar 2020
Takahashi Ken, Seto Yosuke, Okada Koutaroh, Uematsu Shinya, Uchibori Ken, Tsukahara Mika, Oh-Hara Tomoko, Fujita Naoya, Yanagitani Noriko, Nishio Makoto, Okubo Kenichi, Katayama Ryohei
Abstract excerpt
BACKGROUND: Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%-5% of non-small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK-positive NSCLCs. However, the emergence of acquired resistance is inevitable. In this study, we investigated the drugs for overcoming resistance especially compound mutations after sequential treatment with crizotinib, alectinib, and lorlatinib....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.